Paclitaxel Liposome clinical trials
A product of Paclitaxel; its studies count on that page too.
How each study uses Paclitaxel Liposome is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 29 Dec 1992 · TAXOL · NDA 020262 (FDA, Drugs@FDA; as Paclitaxel)
- European Union
- 19 Jul 1999 · Paxene · EMEA/H/C/000216 (EMA; as Paclitaxel; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2008 (3)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2004 | 1 |
| 2008 | 3 |
| 2009 | 2 |
| 2013 | 2 |
| 2014 | 3 |
| 2016 | 2 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 5
Nanjing Luye Sike Pharmaceutical Co., Ltd. (4) · Nanjing Sike Pharmaceutical Co., Ltd. (3) · INSYS Therapeutics Inc (2) · Memorial Sloan Kettering Cancer Center (1) · Shandong Luye Pharmaceutical Co., Ltd. (1) · Fudan University (1) · Sun Yat-sen University (1) · Peking University (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- A dosage form of Paclitaxel
- One of Antimitotic agents source
Studies
Open first, then newest update. How each study uses Paclitaxel Liposome is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- Paclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU)Status unknownPhase 4Nanjing Luye Sike Pharmaceutical Co., Ltd.NCT02996214Written as Paclitaxel LiposomeHow we know
- Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer PatientsStatus unknownPhase 4Fudan UniversityNCT04217096Written as Paclitaxel liposomeHow we know
- Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownPhase 2Sun Yat-sen UniversityNCT03020329Written as Paclitaxel liposomeHow we know
- Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal CancerWithdrawnPhase 3Shantou University Medical CollegeNCT01998347Written as Paclitaxel liposomeHow we know
- Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional TreatmentsStatus unknownPhase 4Nanjing Luye Sike Pharmaceutical Co., Ltd.NCT01994031Written as Paclitaxel liposome injectionHow we know
- Weekly Paclitaxel Liposome Injection Plus Cisplatin in Preoperative Treatment of Breast CancerStatus unknownNot applicableNanjing Luye Sike Pharmaceutical Co., Ltd.NCT02142010Written as paclitaxel liposome injection plus cisplatinHow we know
- Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast CancerStatus unknownPhase 4Nanjing Luye Sike Pharmaceutical Co., Ltd.NCT02142790Written as paclitaxel liposome injectionHow we know
- Study on Neoadjuvant Chemotherapy for Advanced Gastric CancerStatus unknownPhase 2Peking UniversityNCT02163291Written as paclitaxel liposomeHow we know
- PNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the EsophagusCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00016900Written as liposomal paclitaxelHow we know
- Efficacy and Safety Study of LEP-ETU to Treat Metastatic Breast CancerCompletedPhase 2INSYS Therapeutics IncNCT01190982Written as LEP-ETUHow we know
- Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced CancerCompletedPhase 1INSYS Therapeutics IncNCT00100139Written as Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU)How we know
- Clinical Study of Liposomal Paclitaxel in Chinese PatientsStatus unknownPhase 1Nanjing Sike Pharmaceutical Co., Ltd.NCT00881101Written as Liposomal paclitaxelHow we know
- Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric CarcinomaStatus unknownPhase 1Nanjing Sike Pharmaceutical Co., Ltd.NCT00639522Written as Liposomal paclitaxel and capecitabineHow we know
- Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric CarcinomaStatus unknownPhase 1Nanjing Sike Pharmaceutical Co., Ltd.NCT00881816Written as Liposomal paclitaxel plus capecitabineHow we know
- Pharmacokinetics Study of Liposomal Paclitaxel in HumansCompletedPhase 4Shandong Luye Pharmaceutical Co., Ltd.NCT00606515Written as Liposomal paclitaxelHow we know
Given beside what is tested · 10 — Paclitaxel Liposome is usual care or a partner of the new treatment
- Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian CancerRecruitingPhase 2Bai-Rong XiaNCT07125391Written as Paclitaxel liposomeHow we know
- Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung CancerRecruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT05766800Written as Liposomal paclitaxelHow we know
- Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCCRecruitingPhase 3Beijing Tongren HospitalNCT06102395Written as Liposomal paclitaxelHow we know
- Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell CarcinomaNot yet recruitingPhase 1/2The First Affiliated Hospital with Nanjing Medical UniversityNCT06010212Written as Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and NedaplatinHow we know
- Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior ImmunotherapyActive, not recruitingPhase 2Qilu Hospital of Shandong UniversityNCT05585580Written as Paclitaxel/Paclitaxel-albumin/Paclitaxel liposomeHow we know
- Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal CancerStatus unknownPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT03946969Written as Liposomal Paclitaxel + Cisplatin + S-1How we know
- Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal CarcinomaStatus unknownPhase 2Sun Yat-sen UniversityNCT03668730Written as Paclitaxel liposomeHow we know
- Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell CarcinomaStatus unknownPhase 2Wei RenNCT04644250Written as Paclitaxel liposome/CarboplatinHow we know
- SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell CancerStatus unknownPhase 2Chinese Academy of Medical SciencesNCT03603756Written as Paclitaxel liposomeHow we know
- Liposomal Paclitaxel Combined Nedaplatin in Treatment of Advanced or Recurrent Esophageal CarcinomaCompletedPhase 2Sun Yat-sen UniversityNCT02861690Written as Liposomal PaclitaxelHow we know